Jordanië - Engels - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع البتراء للمواد الطبية - petra drug store - palbociclib 125 mg - 125 mg

Jordanië - Engels - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع البتراء للمواد الطبية - petra drug store - palbociclib 75 mg - 75 mg

Jordanië - Engels - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة العربية للمستحضرات الطبية والزراعية - arab company for medical & agricultural products - betamethasone 0.5 mg/g, calcipotriol 50 mcg/g - 0.5 mg/g, 50 mcg/g

Jordanië - Engels - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة العربية للمستحضرات الطبية والزراعية - arab company for medical & agricultural products - betamethasone 0.5 mg/g, calcipotriol 50 mcg/g - 0.5 mg/g, 50 mcg/g

Jordanië - Engels - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع البتراء للمواد الطبية - petra drug store - somatropin 5.3 mg - 5.3 mg

Israël - Engels - Ministry of Health

novartis israel ltd - secukinumab - solution for injection - secukinumab 150 mg/ml - secukinumab - - plaque psoriasis: cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. - paediatric plaque psoriasis: cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy. - psoriatic arthritis: cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (dmard) therapy has been inadequate. - axial spondyloarthritis (axspa) : •ankylosing spondylitis (as, radiographic axial spondyloarthritis) cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. •non-radiographic axial spondyloarthritis (nr-axspa) cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs (nsaids). - juvenile idiopathic arthritis (jia) •enthesitis-related arthritis (era) cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitisrelated arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. •juvenile psoriatic arthritis (jpsa) cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy

Egypte - Engels - EDA (Egyptian Drug Authority)

دلتا ميديكال سنتر -

Egypte - Engels - EDA (Egyptian Drug Authority)

دلتا ميديكال سنتر -

Egypte - Engels - EDA (Egyptian Drug Authority)

دلتا ميديكال سنتر -

Egypte - Engels - EDA (Egyptian Drug Authority)

دلتا ميديكال سنتر -